Optimized dosing for drug coated stents
First Claim
Patent Images
1. A stent coated with paclitaxel, said paclitaxel having a dosage of up to about 2 micrograms per square millimeter of the stent surface area, corresponding to approximate total dosage of 175 micrograms per stent.
2 Assignments
0 Petitions
Accused Products
Abstract
The inventors have found that both the drug dose and drug release profiles are significant factors for the safety and efficacy of drug coated stents. The inventors have identified optimum dosing and release kinetics for drug coated stents. In particular, the inventors have determined dosing and release kinetics that permit the delivery of the lowest effective drug dosage, thus enhancing patient safety and minimizing any side effects from the drug.
214 Citations
36 Claims
- 1. A stent coated with paclitaxel, said paclitaxel having a dosage of up to about 2 micrograms per square millimeter of the stent surface area, corresponding to approximate total dosage of 175 micrograms per stent.
- 2. A stent coated with paclitaxel, said paclitaxel having a dosage of up to about 1 microgram per square millimeter of the stent surface area, corresponding to an approximate total dosage of 85 micrograms per stent.
- 11. A stent coated with paclitaxel, said paclitaxel having a dosage of up to about 2 micrograms per square millimeter of the stent surface area, corresponding to an approximate total dosage of not more than 175 micrograms per stent.
- 12. A stent coated with paclitaxel, said paclitaxel having a dosage of up to about 1 microgram per square millimeter of the stent surface area, corresponding to an approximate total dosage of not more than 85 micrograms per stent.
Specification